SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cellsBO YU; LANE, Maureen E; WADLER, Scott et al.Biochemical pharmacology. 2002, Vol 64, Num 7, pp 1091-1100, issn 0006-2952, 10 p.Article

Histologic precursors of gastrointestinal tract malignancyHABER, Marian M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, viii, 389-412 [24 p.]Article

Barrett's esophagus: Surveillance and treatmentKATZKA, David A.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp ix-x, issn 0889-8588, 18 p.Article

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusionWADLER, Scott; MAKOWER, Della; CLAIRMONT, Caroline et al.Journal of clinical oncology. 2004, Vol 22, Num 9, pp 1553-1563, issn 0732-183X, 11 p.Article

The early diagnosis and prevention of gastrointestinal cancer: Problems and promisesKATZ, Julian; REYNOLDS, James C.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, vii, 351-360 [10 p.]Article

The epidemic of esophageal adenocarcinomaEL-SERAG, Hashem B.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, viii, 413-432 [20 p.]Article

Role of Helicobacter pylori in gastric carcinogenesisSEPULVEDA, Antonia R; GRAHAM, David Y.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, x, 505-523 [19 p.]Article

Cellular and molecular mechanisms of carcinogenesisKATZ, Jonathan P; KAESTNER, Klaus H.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, vii, 361-376 [17 p.]Article

Colorectal cancer in inflammatory bowel disease: Molecular and clinical featuresMURTHY, Sreekant; FLANIGAN, Anne; CLEARFIELD, Harris et al.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp x-xi, issn 0889-8588, 14 p.Article

Diagnosis and management of hereditary colon cancerCRUZ-CORREA, Marcia; GIARDIELLO, Francis M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, xi, 539-551 [13 p.]Article

c-myc/p53 Interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivoARANGO, Diego; CORNER, Georgia A; WADLER, Scott et al.Cancer research (Baltimore). 2001, Vol 61, Num 12, pp 4910-4915, issn 0008-5472Article

Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinomaBEILSTEIN, Michelle; SILBERG, Debra.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, ix, 453-470 [18 p.]Article

Hepatocellular carcinoma: Predisposing conditions and precursor lesionsBAILEY, Marie Ann; BRUNT, Elizabeth M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, xii, 625-646 [12 p.]Article

Pancreatitis as a risk for pancreatic cancerWHITCOMB, David C; POGUE-GEILE, Katherine.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp xii-xiii, issn 0889-8588, 16 p.Article

Decreased short- and long-term Swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinomaSMITH, Richard V; GOLDMAN, S. Yedida; BEITLER, Jonathan J et al.Archives of otolaryngology, head & neck surgery. 2004, Vol 130, Num 7, pp 831-836, issn 0886-4470, 6 p.Article

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-α-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group Study E6296WADLER, Scott; BRAIN, Carlos; CATALANO, Paul et al.The Cancer journal (Sudbury, Mass. Print). 2002, Vol 8, Num 3, pp 282-286, issn 1528-9117Article

Recommended guidelines for the treatment of cancer treatment-induced diarrheaBENSON, Al B; AJANI, Jaffer A; WADLER, Scott et al.Journal of clinical oncology. 2004, Vol 22, Num 14, pp 2918-2926, issn 0732-183X, 9 p.Article

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer : Cancer and leukemia group B 89901RYAN, David P; NIEDZWIECKI, Donna; HOLLIS, Donna et al.Journal of clinical oncology. 2006, Vol 24, Num 16, pp 2557-2562, issn 0732-183X, 6 p.Article

Colon cancer: Detection and preventionLOREN, David E; LEWIS, James; KOCHMAN, Michael L et al.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, xi, 553-574 [22 p.]Article

Fluorouracil modulation in colorectal cancer : Lack of improvement with N-phosphonoacetyl-L-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule: An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B StudyO'DWYER, Peter J; MANOLA, Judith; BENSON, Al B et al.Journal of clinical oncology. 2001, Vol 19, Num 9, pp 2413-2421, issn 0732-183XArticle

A multicenter phase II study of bortezomib in recurrent or metastatic sarcomasMAKI, Robert G; KRAFT, Andrew S; SCHEU, Kelly et al.Cancer. 2005, Vol 103, Num 7, pp 1431-1438, issn 0008-543X, 8 p.Article

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trialROTHENBERG, Mace L; LIU, P. Y; BRALY, Patricia S et al.Journal of clinical oncology. 2003, Vol 21, Num 7, pp 1313-1319, issn 0732-183X, 7 p.Article

Phase II clinical trial of Intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studiesMAKOWER, Della; ROZENBLIT, Alla; KAUFMAN, Howard et al.Clinical cancer research. 2003, Vol 9, Num 2, pp 693-702, issn 1078-0432, 10 p.Article

Phase III trial of Paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup studyOMURA, George A; BRADY, Mark F; LOOK, Katherine Y et al.Journal of clinical oncology. 2003, Vol 21, Num 15, pp 2843-2848, issn 0732-183X, 6 p.Article

Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignanciesGOEL, Sanjay; JHAWER, Minaxi; WADLER, Scott et al.American journal of clinical oncology. 2002, Vol 25, Num 5, pp 528-534, issn 0277-3732, 7 p.Article